US-based medical device firm Neural Analytics has begun patient enrolment for a clinical study of its Lucid M1 Transcranial Doppler (TCD) Ultrasound System to monitor patients with mild traumatic brain injury (TBI).

The Lucid system is developed as an ultrasound system to measure and display cerebral blood flow velocities, as well as to monitor brain disorder patients.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It employs the Transcranial Doppler (TCD) ultrasound to analyse blood vessels in the brain from outside the body.

The two-year study will utilise the system to develop a method for assessing cerebral blood flow in TBI patients and will include 240 subjects who will be divided into mild TBI, 'In Sport' control and Out of Sport control groups.

In Sport controls will comprise subjects associated with high-risk contact sports such as football and hockey, while Out of Sport controls will include low-risk contact sports such as baseball and tennis.

"Findings from this study may help inform physicians on return to play decisions."

Neural Analytics co-founder and chief scientific officer Robert Hamilton said: “There’s a need for a definitive method for mild TBI assessment, in particular for determining if a patient is ready to return to playing after a sports concussion, especially in high school and college athletes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Findings from this study may help inform physicians on return to play decisions.”

Designed to include injury and return-to-participation (RTP) components, the study will primarily focus on new method development for quantification of common post-mild TBI physiologic changes such as impairment of autonomic function and altered cerebral blood flow (CBF).

In the study, the cerebral hemodynamic impairment measured using the Lucid System will be compared to clinical evaluations and magnetic resonance imaging (MRI) techniques.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact